Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Robbins LLPAARD Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Aardvark Therapeutics, Inc.Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's...
- Trade Healthcare, Finance, and Consumer Giants on ZoomexVictoria,Seychelles, Aug. 17, 2026 -- Zoomex has expanded its Stock Perpetuals lineup with twelve new USDT-margined contracts, giving traders 24/7 exposure to some of the most closely watched names in U.S. equities. UnitedHealth Group (UNH), General Electric (GE), JPMorgan Chase (JPM), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Amgen (AMGN), Walmart (WMT), Coca-Cola (KO), PepsiCo (PEP), Mastercard (MA), PayPal Holdings (PYPL), and Berkshire Hathaway Class B (BRK.B) are now live for long and short positions, with no traditional market hours required.
- Robbins LLPDid You Lose Money Investing in Replimune Group, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About their Rights Against REPLShareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period"). Replimune purports to be a clinical-stage biotechnology company focused on novel oncolytic immunotherapies. According to the complaint, the Company's lead product...
- Sagimet Biosciences Inc.Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on August 17, 2026 to the newly hired employees.
- IQVIAIQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest GroupCompanies: IQVIA Holdings, Inc.Everest GroupRESEARCH TRIANGLE PARK, N.C., August 17, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group’s "Top 50™ Pharmaceutical Technology Providers" report for 2026.
- Society for Immunotherapy of Cancer (SITC)SITC Announces 2026 Class of Fellows to the Academy of Immuno-OncologyThe Society for Immunotherapy of Cancer (SITC) is proud to announce the 2026 Class of Fellows of the Academy of Immuno-Oncology (FAIO), recognizing internationally renowned leaders whose pioneering discoveries and enduring contributions have...
- Kaplan Fox & Kilsheimer LLPKaplan Fox Alerts Aardvark Therapeutics, Inc. (AARD) Investors to a Securities Class Action Deadline on October 13, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) on behalf of investors that purchased or otherwise acquired Aardvark common stock pursuant and/or traceable to the Company's initial public offering on or about February 13, 2025, or between February 13, 2025 and May 14, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you...
- The Rosen Law Firm PAROSEN, NATIONAL TRIAL LAWYERS, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPRWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- The Rosen Law Firm PAROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of DirectorsCocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.
- Kaplan Fox & Kilsheimer LLPKaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) for Potential Violations of the Federal Securities LawsKaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also contact...
- AARD INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Aardvark Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the FirmA shareholder class action lawsuit has been filed against Aardvark Therapeutics, Inc. (“Aardvark”) (NASDAQ: AARD). The lawsuit alleges that Defendants, in Aardvark’s Registration Statement and throughout the Class Period, made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (i) ARD-101 was less safe than Defendants had led investors to believe; and (ii) accordingly, ARD-101’s clinical, regulatory, and commercial prospects were overstated.